Miamisburg, Ohio-based Riverain has obtained FDA approval of its latest release of OnGuard Chest X-ray Computer-Aided Detection (CAD) technology, which the company claims to show a 73% reduction in false positive marks and is 50% more sensitive than the old version. Using pattern recognition and machine learning technology, OnGuard detects solitary pulmonary nodules in existing chest X-rays to identify early stage tumors in the lung. The use of existing digital chest X-rays eliminates the need for a separate patient procedure, additional radiation dosage, hardware or stand-alone workstation.
Press release: U.S. FDA approves improved performance of Riverain Medical’s OnGuard Chest X-ray Computer-Aided Detection technology…
Product page: OnGuard…
Flashback: Radiologists Get Software Assistance for Chest X-Ray Analysis